Literature DB >> 24305755

Adjuvant therapy in stage II thymic carcinoma.

Zhengbo Song1, Yiping Zhang.   

Abstract

PURPOSE: The aim of this study is to investigate the impact of chemotherapy and/or radiotherapy on disease-free survival and overall survival for patients with stage II thymic carcinoma.
METHODS: We retrospectively evaluated the outcome of 31 patients with Masaoka stage II thymic carcinoma who were treated between 1995 and 2009 in Zhejiang Cancer Hospital. Survival curves were plotted using the Kaplan-Meier method. The Cox proportional hazard model was used for multivariate analysis.
RESULTS: Thirty-one patients were included in current study. The most common histological subtypes were squamous cell carcinoma (48.4 %), followed by undifferentiated carcinoma (19.4 %) and neuroendocrine tumor (19.4 %).The 5-year disease-free survival and overall survival rate was 74.6 and 89.5 %, respectively. Univariate and multivariate analysis revealed that radiotherapy and/or chemotherapy did not statistically associated with disease-free survival and overall survival.
CONCLUSION: Our result indicated that adjuvant therapy after complete resection could not impact the disease-free survival and overall survival of patients with stage II thymic carcinoma.

Entities:  

Mesh:

Year:  2013        PMID: 24305755     DOI: 10.1007/s00432-013-1562-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  9 in total

1.  Thymic carcinoma: 30 cases at a single institution.

Authors:  Motoki Yano; Hidefumi Sasaki; Tomoki Yokoyama; Haruhiro Yukiue; Osamu Kawano; Sadao Suzuki; Yoshitaka Fujii
Journal:  J Thorac Oncol       Date:  2008-03       Impact factor: 15.609

Review 2.  Chemotherapy of thymic carcinoma: analysis of seven cases and review of the literature.

Authors:  A Kitami; T Suzuki; Y Kamio; S Suzuki
Journal:  Jpn J Clin Oncol       Date:  2001-12       Impact factor: 3.019

Review 3.  Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors: a clinicopathologic study of 108 patients and literature review.

Authors:  Dae Joon Kim; Woo Ick Yang; Sung Sil Choi; Kil Dong Kim; Kyung Young Chung
Journal:  Chest       Date:  2005-03       Impact factor: 9.410

4.  Invasive thymoma: treatment with postoperative radiation therapy.

Authors:  D Latz; P Schraube; U Oppitz; C Kugler; C Manegold; M Flentje; M F Wannenmacher
Journal:  Radiology       Date:  1997-09       Impact factor: 11.105

5.  The role of radiotherapy for thymic carcinoma.

Authors:  Tetsuo Nonaka; Yoshio Tamaki; Keiko Higuchi; Hiroyuki Katoh; Masumi Nakahashi; Hiroyuki Horikoshi; Kenro Takahashi; Koichi Minato; Shiro Sugihara; Masaru Kojima
Journal:  Jpn J Clin Oncol       Date:  2004-12       Impact factor: 3.019

6.  Early-stage thymic carcinoma: is adjuvant therapy required?

Authors:  Mitsuaki Sakai; Takuya Onuki; Masaharu Inagaki; Masatoshi Yamaoka; Shinsuke Kitazawa; Keisuke Kobayashi; Kesato Iguchi; Shinji Kikuchi; Yukinobu Goto; Masataka Onizuka; Yukio Sato
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

7.  Lymphogenous and hematogenous metastasis of thymic epithelial tumors.

Authors:  Kazuya Kondo; Yasumasa Monden
Journal:  Ann Thorac Surg       Date:  2003-12       Impact factor: 4.330

8.  Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan.

Authors:  Kazuya Kondo; Yasumasa Monden
Journal:  Ann Thorac Surg       Date:  2003-09       Impact factor: 4.330

9.  Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a single institution.

Authors:  Chang Young Lee; Mi Kyung Bae; In Kyu Park; Dae Joon Kim; Jin Gu Lee; Kyung Young Chung
Journal:  Eur J Cardiothorac Surg       Date:  2009-03-25       Impact factor: 4.191

  9 in total
  5 in total

1.  Elevated pretreatment serum lactate dehydrogenase level predicts inferior overall survival and disease-free survival after resection of thymic carcinoma.

Authors:  Qianwen Liu; Xiayu Fu; Xiaodong Su; Xin Wang; Yijun Zhang; Hong Yang; Yi Hu; Jing Wen; Jianhua Fu
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

2.  Treatment and survival analyses of completely resected thymic carcinoma patients.

Authors:  Yanjiao Mao; Shixiu Wu
Journal:  Onco Targets Ther       Date:  2015-09-09       Impact factor: 4.147

3.  Treatment and prognosis of Masaoka stage 3 thymic carcinoma: a retrospective study of 32 cases.

Authors:  Yan Sun; Jinshi Liu; Xinmin Yu
Journal:  Onco Targets Ther       Date:  2015-04-06       Impact factor: 4.147

4.  Does size affect the prognosis of resectable thymoma beyond the eighth edition TNM?

Authors:  Yen-Chiang Tseng; Han-Shui Hsu; Yi-Hsuan Lin; Yen-Han Tseng; Chih-Wen Shu; Yih-Gang Goan; Ching-Jiunn Tseng
Journal:  Thorac Cancer       Date:  2021-12-20       Impact factor: 3.500

5.  Postoperative radiotherapy and tumor recurrence after complete resection of stage II/III thymic tumor: a meta-analysis of cohort studies.

Authors:  Jietao Ma; Xin Sun; Letian Huang; Zhicheng Xiong; Meng Yuan; Shuling Zhang; Cheng-Bo Han
Journal:  Onco Targets Ther       Date:  2016-07-22       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.